Literature DB >> 6391849

Double-blind trial of levamisole, penicillamine and azathioprine in rheumatoid arthritis. Clinical, biochemical, radiological and scintigraphic studies.

P Halberg, M W Bentzon, O Crohn, I Gad, O Halskov, J Heyn, M Ingemann, P Junker, I Lorenzen, I Møller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391849

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


× No keyword cloud information.
  6 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Acute phase proteins and clinical synovitis activity in patients with rheumatoid arthritis.

Authors:  M W Bentzon; I Gad; P Halberg; O Halskov; I Lorenzen
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

3.  Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders.

Authors:  K Hørslev-Petersen; K D Bentsen; P Junker; F K Mathiesen; T M Hansen; I Lorenzen
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

4.  Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.

Authors:  K Hørslev-Petersen; K D Bentsen; A Engström-Laurent; P Junker; P Halberg; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

Review 5.  Rational use of disease-modifying antirheumatic drugs.

Authors:  D E Furst
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

6.  Influence of previous gold treatment and other patient variables on outcome of treatment with disease modifying anti-rheumatic drugs (DMARD) in patients with rheumatoid arthritis.

Authors:  M W Bentzon; I Gad; P Halberg; O Halskov; B K Jacobsen; I Lorenzen; N Morling; A Svejgaard
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.